← Back to Screener
Intensity Therapeutics, Inc. Common stock (INTS)
Price$5.21
Favorite Metrics
Price vs S&P 500 (26W)-39.19%
Price vs S&P 500 (4W)-20.86%
Market Capitalization$13.46M
All Metrics
Book Value / Share (Quarterly)$4.70
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-3.66
Price vs S&P 500 (YTD)-52.48%
EPS (TTM)$-11.74
10-Day Avg Trading Volume0.03M
EPS Excl Extra (TTM)$-11.74
EPS (Annual)$-8.56
ROI (Annual)-97.73%
Cash / Share (Quarterly)$4.72
ROA (Last FY)-82.31%
EBITD / Share (TTM)$-8.71
ROE (5Y Avg)-281.35%
Cash Flow / Share (Annual)$-3.66
P/B Ratio1.13x
P/B Ratio (Quarterly)2.07x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-93.78x
ROA (TTM)-148.82%
EPS Incl Extra (Annual)$-8.56
Current Ratio (Annual)5.92x
Quick Ratio (Quarterly)5.55x
3-Month Avg Trading Volume0.06M
52-Week Price Return-88.60%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.16
52-Week High$50.00
EPS Excl Extra (Annual)$-8.56
26-Week Price Return-30.45%
Quick Ratio (Annual)5.55x
13-Week Price Return-50.09%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)5.92x
Enterprise Value$1.544
Revenue / Employee (Annual)$0
Cash / Share (Annual)$4.72
3-Month Return Std Dev98.52%
Net Income / Employee (TTM)$-2
ROE (Last FY)-97.73%
EPS Basic Excl Extra (Annual)$-8.56
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-11.74
ROI (TTM)-214.77%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$-0.39
Price vs S&P 500 (52W)-123.70%
Year-to-Date Return-48.34%
5-Day Price Return-2.93%
EPS Normalized (Annual)$-8.56
ROA (5Y Avg)-213.24%
Month-to-Date Return-9.86%
EBITD / Share (Annual)$-8.69
ROI (5Y Avg)-208.73%
EPS Basic Excl Extra (TTM)$-11.74
P/TBV (Quarterly)2.00x
P/B Ratio (Annual)2.07x
Book Value / Share (Annual)$4.70
Price vs S&P 500 (13W)-52.96%
Beta3.44x
Revenue / Share (TTM)$0.00
ROE (TTM)-214.77%
52-Week Low$4.63
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.08
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
INTSIntensity Therapeutics, Inc. Common stock | — | — | — | — | $5.21 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Intensity Therapeutics is a clinical-stage biotech company developing therapies for solid tumors using its proprietary DfuseRx platform. The company's lead candidate, INT230-6, is administered via direct tumor injection to trigger both localized and systemic immune responses that can target non-injected tumors. Intensity is advancing INT230-6 in metastatic and locally advanced cancer settings where current treatment options are limited.